BFM
PRAX icon

Boothbay Fund Management’s Praxis Precision Medicines PRAX Stock Holding History

Boothbay Fund Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-124,200
Closed -$5.14M – 1862
2024
Q2 		$5.14M Buy
+124,200
New +$5.87M 0.12% 219

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Boothbay Fund Management's PRAX Position: Q1 2026 in Review

Boothbay Fund Management reduced its Praxis Precision Medicines (PRAX) stake by 16% in Q1 2026, selling an estimated $1.05M and leaving 17,587 shares worth $5.67M. The position accounts for 0.07% of the portfolio, ranked #286.

Boothbay Fund Management first reported a position in PRAX in Q3 2021 and has held it in 12 quarters since. The position peaked at $6.18M in Q4 2025. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Boothbay Fund Management held 17,587 shares of Praxis Precision Medicines worth $5.67M as of Q1 2026.
  • Boothbay Fund Management sold 3,387 Praxis Precision Medicines shares in Q1 2026, an estimated $1.05M.
  • Praxis Precision Medicines made up 0.07% of Boothbay Fund Management's portfolio in Q1 2026, its #286 holding.
  • Boothbay Fund Management first reported a position in Praxis Precision Medicines in Q3 2021 and has held it in 12 quarters since.
  • Boothbay Fund Management's Praxis Precision Medicines position peaked at $6.18M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.